Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz, president and chief executive officer at Mirum will present at the virtual Canaccord Genuity 40th Annual Growth Conference on August 13, 2020 at 3:00pm ET.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Friday, August 7, 2020
Information
Tags: 
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Medical specialties, Digestive diseases, Hepatology, Clinical medicine, Alagille syndrome, Progressive familial intrahepatic cholestasis, PFIC, Cholestasis, Genuity
Geotags: 
California, United States
⚠ generated by AI ↴
Organisation: 
MIRUM PHARMACEUTICALS
Summary
Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz, president and chief executive officer at Mirum will present at the virtual Canaccord Genuity 40th Annual Growth Conference on August 13, 2020 at 3:00pm ET.
  • Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.
  • The companys lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
  • Follow Mirum on Twitter , Facebook and LinkedIn .


Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz, president and chief executive officer at Mirum will present at the virtual Canaccord Genuity 40th Annual Growth Conference on August 13, 2020 at 3:00pm ET.

A live audio webcast and an archive of the presentation will be available in the Investors & Media section of the company website at ir.mirumpharma.com.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). For more information, visit mirumpharma.com. Follow Mirum on Twitter, Facebook and LinkedIn.

Copyright: 
Copyright Business Wire 2020